• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    C

    Caribbean Medical University

    院校
    109论文总数
    1,522引用总数

    Caribbean Medical University (CMU) is an independent, for-profit, U.S. curriculum-based medical school. It is located on the island of Curaçao in the southern Caribbean Sea, off the Venezuelan coast. The main campus is located in the Piscadera Bay area of Willemstad. After a total of four years of training, students are awarded the degree of Doctor of Medicine (M.D.).

    论文量&引用量时间轴

    机构学者

    论文(109)

    年份
    起
    –
    止
    排序
    1Comprehensive Review on Myasthenia Gravis: Patho-Physiology, Diagnosis, Management Strategies.
    Ifeoma Nneozor Ozor, Anes Abdulmajid Hwidi, Ammar Ali Khan, Jerrin Jolly Kuriakose, Fatima Hajj, Mary Iwuagwu, Vidhi Kashyap Trivedi, Mostafa Hassan Mohammed Elsayed Hamed, Long Yin Cai

    Myasthenia gravis (MG) is a heterogeneous autoimmune neuromuscular disorder with distinct serological subtypes, including antibodies against acetylcholine receptors (AChRs), MuSK, and LRP4. Despite increasing recognition of these subtypes, clinical practice still lacks a standardized, subtype-specific approach to diagnosis, characterization, and management. Current treatment strategies are often applied uniformly, without fully accounting for differences in disease phenotype, prognosis, and therapeutic response among antibody-defined groups. This review provides a comprehensive overview of adult MG, focusing on the various autoantibody subtypes and their implications for pathogenesis, clinical features, diagnosis, and management. We highlight how combining serological findings with clinical subtyping can inform a more personalized approach to therapy and better align treatment decisions with disease biology. By emphasizing the clinical relevance of serological classification, this review aims to bridge the gap between immunopathological understanding and individualized patient care in MG.

    2026Wiener Medizinische Wochenschrift(2026)引用:73
    引用
    AI阅读
    加入学术空间
    2Comparing the Long-term Outcomes of Coronary Artery Bypass Grafting (CABG) Vs. Percutaneous Coronary Intervention (PCI) in Patients with Multivessel Disease- A Systematic Review and Meta-Analysis.
    Rubela Ray, Shivam Singla, Ghazala S Virk, Sarah Hack, Zaghum Abbas, Hemamalini Anand Murugesan,Arhum Mahmood, Mahnoor Shah, Samra Khalid, Sana Afzal, Izzat

    INTRODUCTION:Coronary Artery Bypass Grafting (CABG) and Percutaneous Coronary Intervention (PCI) are standard treatments for Multivessel Coronary Artery Disease (MVD). Their long-term comparative effectiveness remains debated. METHOD:A systematic review and meta-analysis of randomized and observational studies was conducted, including patients with MVD followed for ≥5 years. Data were pooled using randomor fixed-effects models, depending on the level of heterogeneity. RESULTS:Thirteen studies met the inclusion criteria. CABG was associated with reduced all-cause mortality (RR 0.82, 95% CI 0.72-0.91) and fewer repeat revascularizations (RR 1.98, 95% CI 1.74-2.26) compared with PCI. Stroke risk was slightly higher after CABG. DISCUSSION:Findings suggest CABG provides superior survival and event reduction in long-term follow-up, particularly in higher-risk subgroups. However, the modestly increased stroke risk highlights the need for individualized decision-making, taking into account patient comorbidities, anatomy, and surgical suitability. CONCLUSION:CABG offers long-term survival and durability advantages over PCI in MVD, while PCI remains suitable for patients with lower-risk anatomy or when surgery is contraindicated.

    2026Current cardiology reviews(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Predictors of In-hospital Mortality in Patients with Acute Myocardial Infarction and Obstructive Sleep Apnea: A Nationwide Analysis
    C. A. Gracidas-Carrion, R. H. Levy, C. OLeary, J. Iglesias, J. Varon

    Abstract Introduction/Rationale Acute myocardial infarction (AMI) remains a leading cause of in-hospital mortality. Obstructive sleep apnea (OSA) has increasingly been recognized as a modifiable contributor to adverse cardiovascular outcomes. Patients with AMI and OSA may experience worse clinical outcomes; however, evidence regarding factors associated with in-hospital mortality in this population remains limited. Identifying these factors may enhance risk assessment and management strategies. Methods A retrospective cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2021 was conducted. Adult hospitalizations (≥ 18 years) with primary diagnosis of acute myocardial infarction (ICD-10 I21.0-I21.4, I21.9) and a concurrent diagnosis of obstructive sleep apnea (G47.33) were included. The primary outcome was in-hospital mortality; secondary outcomes included length of hospital stay. Demographics and clinical comorbidities were analyzed as potential predictors of the outcome. Associations between categorical variables and mortality were evaluated using the Chi-square test, with statistical significance set at p < 0.05. Statistical analyses were performed using IBM SPSS Statistics version v25.0. Results A total of 20,771 patients with acute myocardial infarction and obstructive sleep apnea were included, with a mean age of 67 years; 66.3% of the patients were male. The in-hospital mortality rate was 5.2%. Mortality was significantly higher among patients aged ≥60 years (p < 0.001). Race showed a mild association with higher mortality in Caucasian patients (p = 0.03). Comorbid conditions, including chronic kidney disease (p < 0.001), congestive heart failure (p < 0.001), diabetes mellitus (p = 0.032), chronic obstructive pulmonary disease (p = 0.004), and coagulopathy (p = 0.018), were significantly associated with mortality. No significant associations were observed for hypertension, obesity, dyslipidemia, alcohol use, or tobacco use. Discussion Our findings indicate that cardiorenal and pulmonary comorbidities increase the risk of in-hospital mortality in patients with AMI and OSA. These conditions may compromise hemodynamic stability and respiratory function, worsening the ischemic injury and recovery time, leading to longer hospitalizations and poorer outcomes. Conclusion Patients with AMI and OSA present elevated in-hospital mortality, especially when cardiorenal or pulmonary comorbidities coexist. Early identification and targeted management are crucial for reducing mortality and improving patient outcomes. This abstract is funded by: None

    2026AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE(2026)
    引用
    AI阅读
    加入学术空间
    4Persistent Versus Paroxysmal Atrial Fibrillation and Risk of In-Hospital Ischaemic Stroke
    C Gracidas-Carrion, R Levy, C O leary, J Varon

    Abstract Background/Introduction Atrial fibrillation (AF) is a major risk factor for thromboembolic events, particularly ischaemic stroke. AF subtype may reflect differences in arrhythmia burden and atrial remodelling; however, whether persistent AF confers a greater in-hospital stroke risk compared with paroxysmal AF remains uncertain. Purpose To compare the risk of in-hospital ischaemic and embolic stroke between persistent and paroxysmal AF, and to evaluate in-hospital mortality and length of stay (LOS). Methods We conducted a retrospective cohort study using the United States National Inpatient Sample (NIS) from 2018 to 2021. Adult hospitalisations with paroxysmal (ICD-10 code I48.0) or persistent (ICD-10 code I48.1) AF were identified. Primary outcomes were ischaemic stroke (ICD-10 code I63) and embolic stroke (ICD-10 codes I63.1 and I63.4). Secondary outcomes were in-hospital mortality and LOS. Multivariable logistic regression was used to evaluate the independent association between AF subtype and stroke outcomes, adjusting for demographic and clinically relevant cardiovascular and systemic comorbidities. LOS was analysed using linear regression after log transformation (ln[LOS+1]). Results A total of 72,901 AF hospitalisations were identified, of which 20,763 (28.5%) were persistent. Ischaemic stroke occurred in 443 patients (0.6%) and embolic stroke in 166 (0.2%). Overall in-hospital mortality was 1.6%. Persistent AF was independently associated with higher odds of ischaemic stroke compared with paroxysmal AF (OR 1.29; 95% CI 1.05–1.58; p=0.014) and demonstrated a stronger association with embolic stroke (OR 1.67; 95% CI 1.21–2.29; p=0.002). Persistent AF was not independently associated with an increase in in-hospital mortality. In linear regression analysis, persistent AF was associated with longer LOS. After log transformation, persistent AF remained independently associated with prolonged hospitalisation (β 0.094; p<0.001), corresponding to an approximate 9–10% increase in LOS compared with paroxysmal AF. Conclusions Persistent AF is independently associated with increased risk of in-hospital ischaemic and embolic stroke compared with paroxysmal AF, with a stronger association observed for embolic stroke. Persistent AF is also associated with prolonged hospitalisation. These findings highlight the prognostic importance of AF subtype and may support more intensive risk stratification strategies in patients with persistent AF.

    2026European Heart Journal(2026)
    引用
    AI阅读
    加入学术空间
    5Clinical Outcomes Associated with In-Hospital Versus Delayed Outpatient Initiation of Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction
    Helen Oletu, Akinyele Oladimeji, Nneka Muoghalu, Kwasi A Opoku, Azeberoje Osueni, Sunday O Arifayan, Ijeoma A Opara, Emeka Okwuokei, Sylviastella Favour Peteranaba

    BACKGROUND:Heart failure with reduced ejection fraction (HFrEF) remains associated with high rates of hospitalization and early readmission, with approximately 20-25% of patients readmitted within 30 days. Sacubitril/valsartan is a key component of guideline-directed medical therapy, but the optimal timing of initiation during hospitalization versus after discharge remains uncertain. OBJECTIVE:This study aimed to evaluate whether initiation of sacubitril/valsartan during hospitalization is associated with improved short-term outcomes compared with delayed outpatient initiation. METHODS:This retrospective cohort study used the MIMIC-IV database. Adult patients hospitalized with HFrEF who received sacubitril/valsartan were included. Patients were classified into in-hospital initiation and delayed outpatient initiation groups based on medication timing. The primary outcome was 30-day hospital readmission, and the secondary outcome was in-hospital mortality. Multivariable logistic regression was used to assess associations after adjustment for age, sex, race, and the Charlson Comorbidity Index. RESULTS:A total of 4,156 hospitalizations were included. There was no significant association between timing of sacubitril/valsartan initiation and 30-day readmission (aOR=0.91; 95% CI: 0.50-1.67; p=0.764). Higher comorbidity burden was associated with increased readmission risk (aOR=1.04; 95% CI: 1.00-1.07; p=0.035). No significant difference in in-hospital mortality was observed between groups. CONCLUSION:Timing of sacubitril/valsartan initiation was not associated with short-term outcomes. Comprehensive management strategies beyond the timing of therapy may be important for improving outcomes in this population.

    2026Cureus(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 109 篇论文

    合作机构(100)

    聖詹姆斯醫學院合作论文 6
    Smell & Taste Treatment and Research Foundation合作论文 6
    圣路易斯波托西自治大学合作论文 6
    All Saints University Lango合作论文 5
    温莎大学合作论文 4
    Dow University of Health Sciences合作论文 4
    St. George''s University合作论文 4
    普埃布拉大学合作论文 4
    韦恩州立大学合作论文 4
    艾因夏姆斯大学合作论文 4

    机构统计